로딩 중…
지수 로딩 중…
Capricor Therapeutics, Inc.
CAPR· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$4.20+9.09%
2026-08-03
Financials
Valuation Metrics
Capricor Therapeutics, Inc.'s Market Cap is $243M. At end of 2025 it was $1.41B. Ranked #3006 of 3,112 in US market (top 97%), #1362 of 1,445 on NASDAQ (top 94%), #250 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 93%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $243M | US#3,006/3,112 Sec#250/269 |
| Revenue | $0.00 | US#2,974/3,112 Sec#204/269 |
| Net Income | $-115M | US—/3,112 Sec—/269 |
| Total Assets | $326M | US#2,875/3,112 Sec#201/269 |
| Net Assets | $279M | US#2,590/3,112 Sec#167/269 |
| Value | ||
| P/B | 0.87x | US#258/3,112 Sec#11/269 |
| EV/EBITDA | 0.18x | US#1/3,112 Sec#1/269 |
| FCF Yield | -46.85% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -41.12% | US#2,699/3,112 Sec#155/269 |
| ROA | -35.12% | US#2,905/3,112 Sec#177/269 |
| Revenue Growth | -100.00% | US#2,948/3,112 Sec#190/269 |
| Financial Health | ||
| Debt Ratio | 17.07% | US#191/3,112 Sec#71/269 |
| Total Debt | $21M | US#2,689/3,112 Sec#177/269 |
| FCF | $-114M | US#2,610/3,112 Sec#159/269 |
| Cash | $105M | US#2,187/3,112 Sec#175/269 |
| Current Ratio | 8.42x | US#297/3,112 Sec#96/269 |
| Net Debt/EBITDA | -0.09x | US#587/3,112 Sec#32/269 |
| Performance | ||
| 1Y Return | -46.84% | US#2,932/3,112 Sec#240/269 |
| 1M Return | -81.90% | US#3,113/3,112 Sec#269/269 |
| From 52W High | -89.60% | US#3,111/3,112 Sec#268/269 |
| 1Y MDD | -89.11% | US#3,104/3,112 Sec#266/269 |
| Trading | ||
| Volume | 5,086,348 shares | US#359/3,112 Sec#26/269 |
| Trading Value | $20M | US#1,943/3,112 Sec#144/269 |
| Per Share | ||
| EPS | $-2.15 | US—/3,112 Sec—/269 |
| BPS | $6.26 | US#2,103/3,112 Sec#109/269 |